Myositis is a disorder in which the immune system attacks the muscles. It is hoped that this new treatment may help improve the symptoms of this disease.

Research Objectives

Status

Current

Recruitment

Open

Patient Group

Idiopathic Inflammatory Myopathy/Myositis Status: Current

Study location

Wesley Research Institute

Phase

3

Study type

Industry Sponsored

Sponsors: Argenx BV (global) and ICON Clinical Research Pty Ltd (Local)

Lead investigators

Dr Daman Langguth

Clinical Trial Coordinator

Venita Bali

Technical title

A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathies

About this research project

The research project is testing a new treatment for Active Idiopathic Inflammatory Myopathy. This is a disorder in which the immune system attacks the muscles. This leads to muscle weakness and may affect other organs of the body.

The potential new treatment being tested is called efgartigimod (also called ARGX113). It is hoped that efgartigimod may help improve the symptoms of myositis.

Testing treatments to improve symptoms of Myositis